REGENXBIO (RGNX) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
REGENXBIO (RGNX) has outperformed Sana Biotechnology (SANA) over the past year, losing 39.3% versus a loss of 51.7%. Over five years, RGNX leads with a -76.9% price change compared with -91.3% for SANA. Sana Biotechnology is the larger company by market cap ($476.4 million vs $473.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGNX | SANA |
|---|---|---|
| Share price | $7.16 | $1.59 |
| Market cap | $473.44M | $476.42M |
| 1-day change | -0.28% | -8.62% |
| YTD return | -50.28% | -60.93% |
| 1-year return | -39.32% | -51.67% |
| 5-year return | -76.87% | -91.34% |
| EPS (TTM) | $-3.20 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.44M | — |
| Revenue growth (YoY) | +104.54% | — |
| Net income (latest FY) | $-193.88M | $-244.17M |
| Operating margin | -94.58% | — |
| Net margin | -113.75% | — |
| 52-week high | $16.19 | $5.49 |
| 52-week low | $5.46 | $1.57 |
| Distance from 52-week high | -55.78% | -71.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +198.88% | +438.99% |
| Average volume | 1.39M | 3.30M |
| Shares outstanding | 66.12M | 299.63M |
| Employees | 371 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RGNX has outperformed SANA by 12.3 percentage points over the past year.
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
RGNX vs SANA FAQ
Which is bigger, REGENXBIO or Sana Biotechnology?
Sana Biotechnology (SANA) is larger, with a market capitalization of $476.42M compared with $473.44M for REGENXBIO (RGNX).
Which stock has performed better over the past year, RGNX or SANA?
RGNX returned -39.32% over the past 12 months, compared with -51.67% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are REGENXBIO and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.